|drug2423||Patient management suffering of coronavirus infection Wiki||1.00|
|drug3191||Standard of Care Wiki||0.15|
|D000077062||Burnout, Psychological NIH||0.23|
|D013315||Stress, Psychological NIH||0.18|
There is one clinical trial.
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-randomized Control Arm for treatment with standard of care only.
Description: Incidence of adverse events (including serious adverse events and dose limiting toxicities).Measure: Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19 Time: Up to 30 days after dose of CPI-006.
Description: Measure changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.Measure: Immunoglobulin Anti-SARS CoV-2 Levels Time: Baseline and Day 28.
Description: Time to two consecutive negative nasal swab PCR SARS CoV-2 viral tests.Measure: Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests Time: Baseline to two consecutive negative nasal swab PCR SARS CoV-2 viral tests (separated by at least 48 hours).
Description: Duration of COVID-19 related symptoms.Measure: Duration of symptoms Time: Up to 24 weeks after dose of CPI-006.
Description: Time to discharge from hospital.Measure: Time to discharge Time: Up to 24 weeks after dose of CPI-006.
Description: Rate of medical procedures during hospitalization.Measure: Rate of medical procedures Time: Up to 24 weeks after dose of CPI-006.
Description: Difference between Active Arm and Control Arm patients in terms of changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.Measure: Difference in changes in serum/plasma immunoglobulin anti-SARS CoV-2 levels Time: Baseline and visits through Day 28.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports